GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OpGen Inc (LTS:0A8L) » Definitions » Total Liabilities

OpGen (LTS:0A8L) Total Liabilities : $15.46 Mil (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is OpGen Total Liabilities?

OpGen's Total Liabilities for the quarter that ended in Sep. 2023 was $15.46 Mil.

OpGen's quarterly Total Liabilities declined from Mar. 2023 ($17.33 Mil) to Jun. 2023 ($15.58 Mil) and declined from Jun. 2023 ($15.58 Mil) to Sep. 2023 ($15.46 Mil).

OpGen's annual Total Liabilities increased from Dec. 2020 ($28.56 Mil) to Dec. 2021 ($30.45 Mil) but then declined from Dec. 2021 ($30.45 Mil) to Dec. 2022 ($18.24 Mil).


OpGen Total Liabilities Historical Data

The historical data trend for OpGen's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OpGen Total Liabilities Chart

OpGen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.64 6.13 28.56 30.45 18.24

OpGen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.02 18.24 17.33 15.58 15.46

OpGen Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

OpGen's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10.592+(7.417+0.229
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=18.24

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=25.813-7.576
=18.24

OpGen's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.472+(2.83+0.156
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=15.46

Total Liabilities=Total Assets (Q: Sep. 2023 )-Total Equity (Q: Sep. 2023 )
=18.135-2.677
=15.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OpGen Total Liabilities Related Terms

Thank you for viewing the detailed overview of OpGen's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


OpGen (LTS:0A8L) Business Description

Traded in Other Exchanges
Address
9717 Key West Avenue, Suite 100, Rockville, MD, USA, 20850
OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.

OpGen (LTS:0A8L) Headlines

No Headlines